Cancer drug licensed by GSK from China posts promising trial results - Financial Times
Cancer drug licensed by GSK from China posts promising trial results Financial Times
Ovarian Cancer News
GSK reports promising early results in ovarian and womb cancer drug trial - The Guardian
GSK reports promising early results in ovarian and womb cancer drug trial The Guardian
GSK fast-tracks cancer drug that may add billions in annual sales - The Times
GSK fast-tracks cancer drug that may add billions in annual sales The Times
Strong early data prompt GSK to plan five Phase 3 studies for gynecological cancer ADC - Endpoints News
Strong early data prompt GSK to plan five Phase 3 studies for gynecological cancer ADC Endpoints News
Study shows survival benefit of immunotherapy in resistant ovarian cancer - Medical Xpress
Study shows survival benefit of immunotherapy in resistant ovarian cancer Medical Xpress
Rezatapopt Shows Activity in Pretreated Ovarian Cancer With TP53 Mutation - Cure Today
Rezatapopt Shows Activity in Pretreated Ovarian Cancer With TP53 Mutation Cure Today
Targeting senescent fat cells provides new hope for ovarian cancer - News-Medical
Targeting senescent fat cells provides new hope for ovarian cancer News-Medical
Radon Gas Increases Risk Of Ovarian Cancer, Study Says - U.S. News & World Report
Radon Gas Increases Risk Of Ovarian Cancer, Study Says U.S. News & World Report
AbbVie’s Elahere succeeds in Phase II platinum-sensitive ovarian cancer trial - Clinical Trials Arena
AbbVie’s Elahere succeeds in Phase II platinum-sensitive ovarian cancer trial Clinical Trials Arena
Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer - BioSpace
Corcept Presents Complete Data from Pivotal ROSELLA Trial in SGO Late-Breaker with Simultaneous Publication in The Lancet: Lifyorli™ (Relacorilant) Plus Nab-Paclitaxel Improves Overall Survival in Patients with Platinum-Resistant Ovarian Cancer BioSpace
Rethinking ovarian cancer III: the past decade and future directions - Nature
Rethinking ovarian cancer III: the past decade and future directions Nature
Sofetabart Mipitecan Hits 50% Response Rate in Platinum-Resistant Ovarian Cancer - Targeted Oncology
Sofetabart Mipitecan Hits 50% Response Rate in Platinum-Resistant Ovarian Cancer Targeted Oncology
Dr Monk on the KEYNOTE-B96 Data in Recurrent Platinum-Resistant Ovarian Cancer - OncLive
Dr Monk on the KEYNOTE-B96 Data in Recurrent Platinum-Resistant Ovarian Cancer OncLive
GSK advancing ovarian cancer drug mo-rez - statnews.com
GSK advancing ovarian cancer drug mo-rez statnews.com
Florida Cancer Specialists & Research Institute Contributes to Milestone that Expands Treatment Options For Patients With Recurrent Ovarian Cancer - PR Newswire
Florida Cancer Specialists & Research Institute Contributes to Milestone that Expands Treatment Options For Patients With Recurrent Ovarian Cancer PR Newswire
New research links radon exposure to ovarian cancer - WXYZ Channel 7
New research links radon exposure to ovarian cancer WXYZ Channel 7
LIXTE Biotechnology (LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference - Yahoo Finance
LIXTE Biotechnology (LIXT) Reports Interim Ovarian Cancer Trial Results at SGO Conference Yahoo Finance
Data backs GSK's ovarian cancer blockbuster hopes - pharmaphorum
Data backs GSK's ovarian cancer blockbuster hopes pharmaphorum
Phase 3 Survival Data Show Combo Regimen Is a “Game Changer” for Ovarian Cancer - Oncology News Central
Phase 3 Survival Data Show Combo Regimen Is a “Game Changer” for Ovarian Cancer Oncology News Central
Landmark Study Led by Roswell Park Expert Shows Survival Benefit of Immunotherapy in Resistant Ovarian Cancer | Newswise - Newswise
Landmark Study Led by Roswell Park Expert Shows Survival Benefit of Immunotherapy in Resistant Ovarian Cancer | Newswise Newswise
Jes Burns and Brook Herbert win national award for reporting on cancer research - Oregon Public Broadcasting - OPB
Jes Burns and Brook Herbert win national award for reporting on cancer research Oregon Public Broadcasting - OPB
Repurposed drug may extend survival in aggressive ovarian cancer, trial shows - The Guardian
Repurposed drug may extend survival in aggressive ovarian cancer, trial shows The Guardian
Novel B7H3 ADC Yields Responses in Cervical Cancer and Platinum-Resistant Ovarian Cancer - CancerNetwork
Novel B7H3 ADC Yields Responses in Cervical Cancer and Platinum-Resistant Ovarian Cancer CancerNetwork
Mirvetuximab Soravtansine Combo Elicits Antitumor Activity in Platinum-Sensitive Ovarian Cancer - Targeted Oncology
Mirvetuximab Soravtansine Combo Elicits Antitumor Activity in Platinum-Sensitive Ovarian Cancer Targeted Oncology
Dr Olawaiye on the Final OS Data From the Phase 3 ROSELLA Trial in Platinum-Resistant Ovarian Cancer - OncLive
Dr Olawaiye on the Final OS Data From the Phase 3 ROSELLA Trial in Platinum-Resistant Ovarian Cancer OncLive
Relacorilant Plus Nab-Paclitaxel Significantly Improves OS in Platinum-Resistant Ovarian Cancer - OncLive
Relacorilant Plus Nab-Paclitaxel Significantly Improves OS in Platinum-Resistant Ovarian Cancer OncLive
Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference - GlobeNewswire
Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference GlobeNewswire
Radon: Common Household Gas, Tied to Ovarian Cancer Risk - HealthDay
Radon: Common Household Gas, Tied to Ovarian Cancer Risk HealthDay
Rezatapopt Generates Rapid, Durable Responses Across Subgroups in Pretreated TP53 Y220C-Mutated Ovarian Cancer - OncLive
Rezatapopt Generates Rapid, Durable Responses Across Subgroups in Pretreated TP53 Y220C-Mutated Ovarian Cancer OncLive
Radon Gas Increases Risk Of Ovarian Cancer, Study Says - HealthDay
Radon Gas Increases Risk Of Ovarian Cancer, Study Says HealthDay
Mocertatug Rezetecan Displays Early Efficacy, Tolerability in PROC and Endometrial Cancer - OncLive
Mocertatug Rezetecan Displays Early Efficacy, Tolerability in PROC and Endometrial Cancer OncLive
Champions Oncology to present eight studies at AACR 2026 - Drug Target Review
Champions Oncology to present eight studies at AACR 2026 Drug Target Review
SYS6043 Shows Initial Antitumor Activity in Pretreated Ovarian, Endometrial, and Cervical Cancer - OncLive
SYS6043 Shows Initial Antitumor Activity in Pretreated Ovarian, Endometrial, and Cervical Cancer OncLive
Genmab Presents the Safety and Tolerability of Rinatabart - GlobeNewswire
Genmab Presents the Safety and Tolerability of Rinatabart GlobeNewswire
Avutometinib Plus Defactinib Maintains Durable Responses in LGSOC - OncLive
Avutometinib Plus Defactinib Maintains Durable Responses in LGSOC OncLive
Letrozole monotherapy falls short in ovarian cancer clinical trial - News-Medical
Letrozole monotherapy falls short in ovarian cancer clinical trial News-Medical
Michigan Ovarian Cancer Alliance to host Mother's Day 5K and Fun Run - The Eastern Echo
Michigan Ovarian Cancer Alliance to host Mother's Day 5K and Fun Run The Eastern Echo
Radon Exposure Linked to Higher Ovarian Cancer Risk - National Today
Radon Exposure Linked to Higher Ovarian Cancer Risk National Today
Early Promise With REGN5668 Combinations in Gynecologic Cancers - Targeted Oncology
Early Promise With REGN5668 Combinations in Gynecologic Cancers Targeted Oncology
GSK announces positive outcomes from Phase I BEHOLD-1 trial of Mo-Rez - Clinical Trials Arena
GSK announces positive outcomes from Phase I BEHOLD-1 trial of Mo-Rez Clinical Trials Arena